FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367183567> ?p ?o ?g. }

• W4367183567 endingPage "2489" @default.
• W4367183567 startingPage "2489" @default.
• W4367183567 abstract "Stereotactic ablative radiotherapy (SABR) and stereotactic radiosurgery (SRS) with conventional photon radiotherapy (XRT) are well-established treatment options for selected patients with oligometastatic/oligorecurrent disease. The use of PBT for SABR-SRS is attractive given the property of a lack of exit dose. The aim of this review is to evaluate the role and current utilisation of PBT in the oligometastatic/oligorecurrent setting.Using Medline and Embase, a comprehensive literature review was conducted following the PICO (Patients, Intervention, Comparison, and Outcomes) criteria, which returned 83 records. After screening, 16 records were deemed to be relevant and included in the review.Six of the sixteen records analysed originated in Japan, six in the USA, and four in Europe. The focus was oligometastatic disease in 12, oligorecurrence in 3, and both in 1. Most of the studies analysed (12/16) were retrospective cohorts or case reports, two were phase II clinical trials, one was a literature review, and one study discussed the pros and cons of PBT in these settings. The studies presented in this review included a total of 925 patients. The metastatic sites analysed in these articles were the liver (4/16), lungs (3/16), thoracic lymph nodes (2/16), bone (2/16), brain (1/16), pelvis (1/16), and various sites in 2/16.PBT could represent an option for the treatment of oligometastatic/oligorecurrent disease in patients with a low metastatic burden. Nevertheless, due to its limited availability, PBT has traditionally been funded for selected tumour indications that are defined as curable. The availability of new systemic therapies has widened this definition. This, together with the exponential growth of PBT capacity worldwide, will potentially redefine its commissioning to include selected patients with oligometastatic/oligorecurrent disease. To date, PBT has been used with encouraging results for the treatment of liver metastases. However, PBT could be an option in those cases in which the reduced radiation exposure to normal tissues leads to a clinically significant reduction in treatment-related toxicities." @default.
• W4367183567 created "2023-04-28" @default.
• W4367183567 creator A5007143079 @default.
• W4367183567 creator A5009369056 @default.
• W4367183567 creator A5009792664 @default.
• W4367183567 creator A5011844809 @default.
• W4367183567 creator A5017386678 @default.
• W4367183567 creator A5025579028 @default.
• W4367183567 creator A5048227547 @default.
• W4367183567 creator A5051121860 @default.
• W4367183567 creator A5054413808 @default.
• W4367183567 creator A5057696542 @default.
• W4367183567 creator A5058318470 @default.
• W4367183567 creator A5067595603 @default.
• W4367183567 creator A5067974190 @default.
• W4367183567 creator A5071970248 @default.
• W4367183567 creator A5077522160 @default.
• W4367183567 date "2023-04-26" @default.
• W4367183567 modified "2023-10-14" @default.
• W4367183567 title "Proton Beam Therapy in the Oligometastatic/Oligorecurrent Setting: Is There a Role? A Literature Review" @default.
• W4367183567 cites W1573174491 @default.
• W4367183567 cites W1974786165 @default.
• W4367183567 cites W2024501410 @default.
• W4367183567 cites W2025972591 @default.
• W4367183567 cites W2030505692 @default.
• W4367183567 cites W2066990861 @default.
• W4367183567 cites W2083770395 @default.
• W4367183567 cites W2088689722 @default.
• W4367183567 cites W2113154114 @default.
• W4367183567 cites W2113258467 @default.
• W4367183567 cites W2114932214 @default.
• W4367183567 cites W2117573977 @default.
• W4367183567 cites W2127199535 @default.
• W4367183567 cites W2128871519 @default.
• W4367183567 cites W2136716437 @default.
• W4367183567 cites W2163678892 @default.
• W4367183567 cites W2321778825 @default.
• W4367183567 cites W2620136525 @default.
• W4367183567 cites W2744169094 @default.
• W4367183567 cites W2758334036 @default.
• W4367183567 cites W2766619605 @default.
• W4367183567 cites W2791982818 @default.
• W4367183567 cites W2795467679 @default.
• W4367183567 cites W2804817390 @default.
• W4367183567 cites W2809603358 @default.
• W4367183567 cites W2889974110 @default.
• W4367183567 cites W2912954993 @default.
• W4367183567 cites W2930757652 @default.
• W4367183567 cites W2940075519 @default.
• W4367183567 cites W2947927504 @default.
• W4367183567 cites W2969929990 @default.
• W4367183567 cites W2972955865 @default.
• W4367183567 cites W2992659247 @default.
• W4367183567 cites W3012767602 @default.
• W4367183567 cites W3013532219 @default.
• W4367183567 cites W3016742464 @default.
• W4367183567 cites W3019546741 @default.
• W4367183567 cites W3023823461 @default.
• W4367183567 cites W3032651552 @default.
• W4367183567 cites W3039456237 @default.
• W4367183567 cites W3048519025 @default.
• W4367183567 cites W3092883299 @default.
• W4367183567 cites W3107300149 @default.
• W4367183567 cites W3108078206 @default.
• W4367183567 cites W3121587072 @default.
• W4367183567 cites W3128662756 @default.
• W4367183567 cites W3131896404 @default.
• W4367183567 cites W3133011019 @default.
• W4367183567 cites W3135238037 @default.
• W4367183567 cites W3136016043 @default.
• W4367183567 cites W3143155775 @default.
• W4367183567 cites W3149745570 @default.
• W4367183567 cites W3166370211 @default.
• W4367183567 cites W3185172283 @default.
• W4367183567 cites W3185339731 @default.
• W4367183567 cites W3193233808 @default.
• W4367183567 cites W3203161385 @default.
• W4367183567 cites W3208585046 @default.
• W4367183567 cites W3214304345 @default.
• W4367183567 cites W4206152410 @default.
• W4367183567 cites W4210366827 @default.
• W4367183567 cites W4212958709 @default.
• W4367183567 cites W4220845135 @default.
• W4367183567 cites W4225536341 @default.
• W4367183567 cites W4240340450 @default.
• W4367183567 cites W4280521662 @default.
• W4367183567 cites W4281761532 @default.
• W4367183567 cites W4291398395 @default.
• W4367183567 cites W4296520337 @default.
• W4367183567 cites W4307773742 @default.
• W4367183567 cites W4313566601 @default.
• W4367183567 cites W4313574615 @default.
• W4367183567 cites W4319769758 @default.
• W4367183567 cites W4320883683 @default.
• W4367183567 doi "https://doi.org/10.3390/cancers15092489" @default.
• W4367183567 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37173955" @default.
• W4367183567 hasPublicationYear "2023" @default.
• W4367183567 type Work @default.

• next